ClinicalTrials.gg
CompletedNCT00721409Updated Nov 4, 2019Results posted

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

A Phase 2 interventional study of PD 0332991 and letrozole in Breast Cancer, sponsored by Pfizer. Completed at 104 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-04.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.

Enrollment
37th of 111
177 · median 100
Started
2008
the only one that year
Phase 2
62 of 111
8 open now
Registered
1st of 111
by date
Lead sponsor
10 of 111
Pfizer

Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 37th largest by enrollment, is the only one that started in 2008, is one of 62 in phase 2, and was the 1st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About palbociclib

palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing palbociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • hormone-receptor positive advanced breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inoperable estrogen receptor positive and negative breast cancer.
  • status.
  • Tumor tissue (archived acceptable) available for biomarker studies. For Phase 2 Part 2 - CCND1 amplification and/or loss of p16 as determined by the central laboratory.
  • Acceptable bone marrow, liver and kidney function.

Exclusion criteria

Exclusion Criteria:

  • Prior or concomitant treatment for advanced breast cancer.
  • Other major cancer in the past 3 years.
  • Important cardiovascular events in the past 6 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Arm A

    letrozole + PD 0332991

    Drug: PD 0332991 · Drug: letrozole

  • Active comparator
    Arm B

    letrozole

    Drug: letrozole

Interventions

  • 125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles

  • 2.5 mg/d tablets orally on a continuous regimen

  • 2.5 mg/d tablets orally on a continuous regimen

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Maximum treatment duration (approximately 55 months)

  2. Number of Participants With Treatment-Related Adverse Events at Phase 1

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Maximum treatment duration (approximately 55 months)

  3. Number of Participants With Dose Limiting Toxicities at Phase 1

    Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets \<25,000/μL, ANC \<500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count \<50,000/μL; ANC \<1,000/μL; nonhematologic toxicities of Grade ≥3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment.

    Time frame: Cycle 2 (4 weeks)

  4. Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment

    PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs).

    Time frame: From randomization date to date of first documentation of progression or death (assessed up to 41 months)

Secondary outcomes

  1. Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1

    Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.

    Time frame: From Baseline up to end of study (assessed up to 55 months)

  2. Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1

    CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging \>= 4 weeks after initial response.

    Time frame: From Baseline up to end of study (assessed up to 55 months)

  3. Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1

    On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

    Time frame: Cycle 1 Day 14, and Cycle 2 Day 14

  4. Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1

    On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

    Time frame: Cycle 1 Day 14, and Cycle 2 Day 14

  5. Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1

    On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

    Time frame: Cycle 1 Day 14, and Cycle 2 Day 14

  6. Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1

    On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

    Time frame: Cycle 1 Day 14, and Cycle 2 Day 14

  7. Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1

    On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

    Time frame: Cycle 1 Day 14, and Cycle 2 Day 14

  8. Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1

    On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

    Time frame: Cycle 1 Day 14, and Cycle 2 Day 14

  9. Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1

    On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.

    Time frame: Cycle 2 Day 14, Cycle 2 Day 28

  10. Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1

    On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.

    Time frame: Cycle 2 Day 14, and Cycle 2 Day 28

  11. Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1

    On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.

    Time frame: Cycle 2 Day 14, and Cycle 2 Day 28

  12. Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.

    Time frame: Cycle 1 Day 1 prior to dosing, Cycle 1 Day 14 (2, 4 [prior to meal], 8, 24, 48, and 96 hours after dosing of Palbociclib), Cycle 2 Day 1 and Day 14 (prior to and 4 hours after dosing of letrozole)

  13. Overall Survival (OS) at Phase 2

    Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months.

    Time frame: From randomization until death (assessed up to 86 months)

  14. Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment

    Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.

    Time frame: From randomization up to the end of treatment (approximately 41 months)

  15. Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment

    Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes).

    Time frame: From randomization up to the end of treatment (approximately 41 months)

  16. Duration of Response at Phase 2 - Investigator Assessment

    Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).

    Time frame: From randomization up to the end of treatment (approximately 41 months)

  17. Number of Participants With CBR at Phase 2 - Investigator Assessment

    CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST.

    Time frame: From randomization up to the end of treatment (approximately 41 months)

  18. Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment

    Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).

    Time frame: From randomization up to the end of treatment (approximately 41 months)

  19. Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2

    The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").

    Time frame: Baseline, End of treatment (approximately 41 months)

  20. Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2

    The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").

    Time frame: Baseline, End of treatment (approximately 41 months)

  21. Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1

    Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples.

    Time frame: Screening visit (≤ 28 Days prior to dosing)

  22. Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67

    Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups.

    Time frame: Screening visit (≤ 28 Days prior to dosing)

  23. Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1

    Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression \>0 and Negative: any expression=0.

    Time frame: Screening visit (≤ 28 Days prior to dosing)

  24. Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2

    Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group.

    Time frame: Screening visit (≤ 28 Days prior to dosing)

  25. Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2

    One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed.

    Time frame: Screening visit (≤ 28 Days prior to dosing)

  26. Number of Participants With TEAEs (All Causalities) at Phase 2

    AE:any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non-serious AEs.SAE:AE resulting in any of following outcomes/deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason:death;initial or prolonged inpatient hospitalization;life-threatening experience (immediate risk of dying);persistent or significant disability/incapacity;congenital anomaly.Treatment emergent AEs:events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or worsened relative to pre-treatment state.AEs were graded as per the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and coded using Medical Dictionary for Regulatory Activities (MedDRA). Participants with AE of grade 3 or 4 and grade 5 were reported as Grade 3:Severe, Grade 4:Life threatening, Grade 5:Death related to AE.

    Time frame: Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)

  27. Number of Participants With Treatment-Related Adverse Events at Phase 2

    AE: any untoward medical occurrence in a participant who received study drug. AEs included both serious and non-serious adverse events. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs: events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Treatment related AEs: all AEs with causality related to treatment. Relatedness to drug was assessed by the investigator. AEs were graded according to the CTCAE version 3.0 and coded using the MedDRA. Number of participants with AE of grade 3 or 4 and with AE of grade 5 were reported as Grade 3: Severe, Grade 4: Life threatening, Grade 5: Death related to AE.

    Time frame: Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)

07

Results

Posted Mar 19, 2015

Participant flow

This Phase 1/2, open-label, randomized study enrolled a total of 12 participants at 3 sites in the United States for Phase 1. Phase 1 participants received Palbociclib + Letrozole. In Phase 2, a total of 165 participants were randomized (84 in palbociclib plus letrozole arm and 81 in letrozole alone arm) at 50 sites in 12 countries.

Participant flow — Overall Study
MilestonePhase 1 (Palbociclib + Letrozole)Phase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)
Started128481
Treated128377
Completed022
Not completed128279
Withdrew: Global deterioration of health status263
Withdrew: Death010
Withdrew: Randomized not treated014
Withdrew: Reason not specified102
Withdrew: Adverse event0132
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject165
Withdrew: Objective progression or relapse85562

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Maximum treatment duration (approximately 55 months)
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1
ParticipantsPhase 1 (Palbociclib + Letrozole)
Participants with AEs12
Participants with SAEs2
Participants with Grade 3 or 4 AEs11
Participants with Grade 5 AEs0
PrimaryNumber of Participants With Treatment-Related Adverse Events at Phase 1

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Maximum treatment duration (approximately 55 months)
Reported as:
Number · Participants
Number of Participants With Treatment-Related Adverse Events at Phase 1
ParticipantsPhase 1 (Palbociclib + Letrozole)
Participants with AEs12
Participants with SAEs0
Participants with Grade 3 or 4 AEs11
Participants with Grade 5 AEs0
PrimaryNumber of Participants With Dose Limiting Toxicities at Phase 1

Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets \<25,000/μL, ANC \<500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count \<50,000/μL; ANC \<1,000/μL; nonhematologic toxicities of Grade ≥3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment.

Time frame:
Cycle 2 (4 weeks)
Reported as:
Number · Participants
Number of Participants With Dose Limiting Toxicities at Phase 1
ParticipantsPhase 1 (Palbociclib + Letrozole)
Grade 4 Neutropenia2
<80% of doses due to elevated creatinine1
PrimaryProgression-Free Survival (PFS) at Phase 2 - Investigator Assessment

PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs).

Time frame:
From randomization date to date of first documentation of progression or death (assessed up to 41 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment
MonthsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment20.2 (13.8 to 27.5)10.2 (5.7 to 12.6)26.1 (11.2 to NA)5.7 (2.6 to 10.5)18.1 (13.1 to 27.5)11.1 (7.1 to 16.4)
Statistical analysis
  • Phase 2 (Palbociclib + Letrozole) vs Phase 2 (Letrozole) · Log Rank · p = 0.0004 (1-sided p-value from the log-rank test stratified by stratification factors per randomization and Part.) · Hazard ratio (hr): 0.488 · 95% CI 0.319 to 0.748
  • Ph2P1 (Palbociclib + Letrozole) vs Ph2P1 (Letrozole) · Log Rank · p = <0.0001 (1-sided p-value from the log-rank test.) · Hazard ratio (hr): 0.299 · 95% CI 0.156 to 0.572
  • Ph2P2 (Palbociclib + Letrozole) vs Ph2P2 (Letrozole) · Log Rank · p = 0.0046 (1-sided p-value from the log-rank test.) · Hazard ratio (hr): 0.508 · 95% CI 0.303 to 0.853
SecondaryObjective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1

Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.

Time frame:
From Baseline up to end of study (assessed up to 55 months)
Reported as:
Number · Percentage of participants
Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1
Percentage of participantsPhase 1 (Palbociclib + Letrozole)
Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 133.3 (9.9 to 65.1)
SecondaryPercentage of Participants With Clinical Benefit Response (CBR) at Phase 1

CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging \>= 4 weeks after initial response.

Time frame:
From Baseline up to end of study (assessed up to 55 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1
Percentage of participantsPhase 1 (Palbociclib + Letrozole)
Percentage of Participants With Clinical Benefit Response (CBR) at Phase 183.3 (51.6 to 97.9)
SecondarySummary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1

On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

Time frame:
Cycle 1 Day 14, and Cycle 2 Day 14
Reported as:
Geometric mean · ng·hr/mL
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1
ng·hr/mLPalbociclib Alone (Cycle 1 Day 14)Palbociclib + Letrozole (Cycle 2 Day 14)
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 11982 ± 291933 ± 31
SecondarySummary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1

On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

Time frame:
Cycle 1 Day 14, and Cycle 2 Day 14
Reported as:
Geometric mean · ng/mL
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1
ng/mLPalbociclib Alone (Cycle 1 Day 14)Palbociclib + Letrozole (Cycle 2 Day 14)
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1115.8 ± 28108.4 ± 29
SecondarySummary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1

On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

Time frame:
Cycle 1 Day 14, and Cycle 2 Day 14
Reported as:
Median · Hour
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1
HourPalbociclib Alone (Cycle 1 Day 14)Palbociclib + Letrozole (Cycle 2 Day 14)
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 17.92 ± 287.92 ± 29
SecondarySummary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1

On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

Time frame:
Cycle 1 Day 14, and Cycle 2 Day 14
Reported as:
Mean · Hour
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1
HourPalbociclib Alone (Cycle 1 Day 14)Palbociclib + Letrozole (Cycle 2 Day 14)
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 128.81 ± 5.0462NA ± NA
SecondarySummary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1

On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

Time frame:
Cycle 1 Day 14, and Cycle 2 Day 14
Reported as:
Geometric mean · L/hr
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1
L/hrPalbociclib Alone (Cycle 1 Day 14)Palbociclib + Letrozole (Cycle 2 Day 14)
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 163.08 ± 29NA ± NA
SecondarySummary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1

On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.

Time frame:
Cycle 1 Day 14, and Cycle 2 Day 14
Reported as:
Geometric mean · L
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1
LPalbociclib Alone (Cycle 1 Day 14)Palbociclib + Letrozole (Cycle 2 Day 14)
Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 12583 ± 26NA ± NA
SecondarySummary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1

On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.

Time frame:
Cycle 2 Day 14, Cycle 2 Day 28
Reported as:
Geometric mean · ng·hr/mL
Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1
ng·hr/mLPalbociclib + Letrozole (Cycle 2 Day 14)Letrozole Alone (Cycle 2 Day 28)
Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 11739 ± 301936 ± 35
SecondarySummary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1

On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.

Time frame:
Cycle 2 Day 14, and Cycle 2 Day 28
Reported as:
Geometric mean · ng/mL
Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1
ng/mLPalbociclib + Letrozole (Cycle 2 Day 14)Letrozole Alone (Cycle 2 Day 28)
Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 194.95 ± 27104.0 ± 31
SecondarySummary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1

On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.

Time frame:
Cycle 2 Day 14, and Cycle 2 Day 28
Reported as:
Median · Hour
Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1
HourPalbociclib + Letrozole (Cycle 2 Day 14)Letrozole Alone (Cycle 2 Day 28)
Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 12.00 ± 271.04 ± 31
SecondaryNumber of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized.

Time frame:
Cycle 1 Day 1 prior to dosing, Cycle 1 Day 14 (2, 4 [prior to meal], 8, 24, 48, and 96 hours after dosing of Palbociclib), Cycle 2 Day 1 and Day 14 (prior to and 4 hours after dosing of letrozole)
Reported as:
Number · Participants
Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1
ParticipantsPhase 1 (Palbociclib + Letrozole)
QTcB - Change <309
QTcB - 30 ≤ change <603
QTcB - Change ≥600
QTcF - Change <3011
QTcF - 30 ≤ change <601
QTcF - Change ≥600
QTcS - Change <308
QTcS - 30 ≤ change <604
QTcS - Change ≥600
SecondaryOverall Survival (OS) at Phase 2

Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months.

Time frame:
From randomization until death (assessed up to 86 months)
Reported as:
Median · Months
Overall Survival (OS) at Phase 2
MonthsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Overall Survival (OS) at Phase 237.5 (31.4 to 47.8)34.5 (27.4 to 42.6)37.5 (27.6 to 58.8)33.3 (26.0 to 54.3)35.1 (28.1 to 47.8)35.7 (26.6 to 46.7)
Statistical analysis
  • Phase 2 (Palbociclib + Letrozole) vs Phase 2 (Letrozole) · Log Rank · p = 0.2812 (1-sided p-value from the log-rank test stratified by Part (α = 0.10).) · Hazard ratio (hr): 0.897 · 95% CI 0.623 to 1.294
  • Ph2P1 (Palbociclib + Letrozole) vs Ph2P1 (Letrozole) · Log Rank · p = 0.2803 (1-sided p-value from the unstratified log-rank test (α=0.10).) · Hazard ratio (hr): 0.837 · 95% CI 0.458 to 1.527
  • Ph2P2 (Palbociclib + Letrozole) vs Ph2P2 (Letrozole) · Log Rank · p = 0.3875 (1-sided p-value from the unstratified log-rank test (α=0.10).) · Hazard ratio (hr): 0.935 · 95% CI 0.590 to 1.480
SecondaryObjective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment

Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.

Time frame:
From randomization up to the end of treatment (approximately 41 months)
Reported as:
Number · Percentage of participants
Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment
Percentage of participantsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment42.9 (32.1 to 54.1)33.3 (23.2 to 44.7)44.1 (27.2 to 62.1)25.0 (11.5 to 43.4)42.0 (28.2 to 56.8)38.8 (25.2 to 53.8)
Statistical analysis
  • Phase 2 (Palbociclib + Letrozole) vs Phase 2 (Letrozole) · Cochran-Mantel-Haenszel · p = 0.1347 (1-sided p-value is from the stratified exact test (1-sided, α =0.10)) · Odds ratio (or): 1.50 · 95% CI 0.76 to 2.97
  • Ph2P1 (Palbociclib + Letrozole) vs Ph2P1 (Letrozole) · Chi-squared · p = 0.0849 (Chi-square test was used (1-sided, α=0.10)) · Odds ratio (or): 2.37 · 95% CI 0.74 to 7.84
  • Ph2P2 (Palbociclib + Letrozole) vs Ph2P2 (Letrozole) · Chi-squared · p = 0.4515 (Chi-square test was used (1-sided, α=0.10)) · Odds ratio (or): 1.14 · 95% CI 0.48 to 2.76
SecondaryObjective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment

Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes).

Time frame:
From randomization up to the end of treatment (approximately 41 months)
Reported as:
Number · Percentage of participants
Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment
Percentage of participantsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment55.4 (42.5 to 67.7)39.4 (27.6 to 52.2)55.6 (35.3 to 74.5)34.8 (16.4 to 57.3)55.3 (38.3 to 71.4)41.9 (27.0 to 57.9)
Statistical analysis
  • Phase 2 (Palbociclib + Letrozole) vs Phase 2 (Letrozole) · Cochran-Mantel-Haenszel · p = 0.0471 (1-sided p-value is from the stratified exact test (1-sided, α =0.10)) · Odds ratio (or): 1.93 · 95% CI 0.91 to 4.08
  • Ph2P1 (Palbociclib + Letrozole) vs Ph2P1 (Letrozole) · Chi-squared · p = 0.1180 (Chi-square test was used (1-sided, α=0.10)) · Odds ratio (or): 2.34 · 95% CI 0.65 to 8.66
  • Ph2P2 (Palbociclib + Letrozole) vs Ph2P2 (Letrozole) · Chi-squared · p = 0.1631 (Chi-square test was used (1-sided, α=0.10)) · Odds ratio (or): 1.72 · 95% CI 0.65 to 4.54
SecondaryDuration of Response at Phase 2 - Investigator Assessment

Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).

Time frame:
From randomization up to the end of treatment (approximately 41 months)
Reported as:
Median · Months
Duration of Response at Phase 2 - Investigator Assessment
MonthsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Duration of Response at Phase 2 - Investigator Assessment20.3 (13.4 to 25.8)11.1 (9.3 to 31.6)20.9 (6.2 to 25.8)10.8 (3.7 to 31.6)20.2 (13.0 to NA)14.8 (7.4 to NA)
SecondaryNumber of Participants With CBR at Phase 2 - Investigator Assessment

CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST.

Time frame:
From randomization up to the end of treatment (approximately 41 months)
Reported as:
Number · Percentage of participants
Number of Participants With CBR at Phase 2 - Investigator Assessment
Percentage of participantsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Number of Participants With CBR at Phase 2 - Investigator Assessment81.0 (70.9 to 88.7)58.0 (46.5 to 68.9)76.5 (58.8 to 89.3)43.8 (26.4 to 62.3)84.0 (70.9 to 92.8)67.3 (52.5 to 80.1)
Statistical analysis
  • Phase 2 (Palbociclib + Letrozole) vs Phase 2 (Letrozole) · Cochran-Mantel-Haenszel · p = 0.0009 (1-sided p-value is from the stratified exact test (1-sided, α =0.10).) · Odds ratio (or): 3.18 · 95% CI 1.48 to 6.98
  • Ph2P1 (Palbociclib + Letrozole) vs Ph2P1 (Letrozole) · Chi-squared · p = 0.0065 (Chi-square test was used (1-sided, α=0.10)) · Odds ratio (or): 4.18 · 95% CI 1.30 to 13.90
  • Ph2P2 (Palbociclib + Letrozole) vs Ph2P2 (Letrozole) · Chi-squared · p = 0.0442 (Chi-square test was used (1-sided, α=0.10)) · Odds ratio (or): 2.55 · 95% CI 0.89 to 7.70
SecondaryTime to Tumor Progression (TTP) at Phase 2-Investigator Assessment

Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).

Time frame:
From randomization up to the end of treatment (approximately 41 months)
Reported as:
Median · Months
Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment
MonthsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment20.2 (13.8 to 27.5)10.2 (5.7 to 12.6)26.1 (11.2 to NA)5.7 (2.6 to 10.5)18.8 (13.1 to 27.5)11.1 (7.1 to 16.4)
Statistical analysis
  • Phase 2 (Palbociclib + Letrozole) vs Phase 2 (Letrozole) · Log Rank · p = <0.0001 (1-sided p-value is from the stratified log-rank test (α =0.10).) · Hazard ratio (hr): 0.399 · 95% CI 0.265 to 0.601
  • Ph2P1 (Palbociclib + Letrozole) vs Ph2P1 (Letrozole) · Log Rank · p = <0.0001 (1-sided p-value is from unstratified log-rank test (α=0.10).) · Hazard ratio (hr): 0.299 · 95% CI 0.156 to 0.572
  • Ph2P2 (Palbociclib + Letrozole) vs Ph2P2 (Letrozole) · Log Rank · p = 0.0030 (1-sided p-value is from unstratified log-rank test (α=0.10).) · Hazard ratio (hr): 0.486 · 95% CI 0.288 to 0.822
SecondaryChange From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2

The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").

Time frame:
Baseline, End of treatment (approximately 41 months)
Reported as:
Mean · Units on a scale
Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2
Units on a scalePhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Pain at its worst in the last 24 hours0.6 ± 0.420.1 ± 0.420.2 ± 0.600.0 ± 0.891.2 ± 0.550.1 ± 0.43
Pain at its least in the last 24 hours0.4 ± 0.270.4 ± 0.270.3 ± 0.310.7 ± 0.500.5 ± 0.400.2 ± 0.31
Pain on the average0.2 ± 0.330.2 ± 0.34-0.1 ± 0.480.2 ± 0.640.4 ± 0.450.3 ± 0.40
Pain right now0.3 ± 0.350.1 ± 0.360.1 ± 0.310.3 ± 0.660.3 ± 0.550.0 ± 0.43
Pain Severity Scale0.4 ± 0.290.2 ± 0.320.0 ± 0.360.3 ± 0.620.6 ± 0.410.1 ± 0.36
Statistical analysis
  • Phase 2 (Palbociclib + Letrozole) vs Phase 2 (Letrozole) · t-test, 2 sided · p = 0.6900 (P-values are based on 2-sample t-test.) · Mean difference (final values): 0.2 · 95% CI -0.7 to 1.0
  • Ph2P1 (Palbociclib + Letrozole) vs Ph2P1 (Letrozole) · t-test, 2 sided · p = 0.7125 (P-values are based on 2-sample t-test.) · Mean difference (final values): -0.3 · 95% CI -1.8 to 1.2
  • Ph2P2 (Palbociclib + Letrozole) vs Ph2P2 (Letrozole) · t-test, 2 sided · p = 0.4012 (P-values are based on 2-sample t-test.) · Mean difference (final values): 0.5 · 95% CI -0.6 to 1.5
SecondaryChange From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2

The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").

Time frame:
Baseline, End of treatment (approximately 41 months)
Reported as:
Mean · Units on a scale
Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2
Units on a scalePhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
General Activity1.1 ± 0.400.2 ± 0.311.0 ± 0.660.2 ± 0.581.2 ± 0.510.3 ± 0.37
Mood0.8 ± 0.500.2 ± 0.360.6 ± 0.72-0.2 ± 0.621.0 ± 0.690.4 ± 0.44
Walking ability0.8 ± 0.460.1 ± 0.351.0 ± 0.550.3 ± 0.630.7 ± 0.670.0 ± 0.43
Normal work0.7 ± 0.480.3 ± 0.391.0 ± 0.530.2 ± 0.740.5 ± 0.710.4 ± 0.45
Relations0.8 ± 0.320.8 ± 0.320.6 ± 0.340.6 ± 0.600.9 ± 0.470.8 ± 0.37
Sleep0.6 ± 0.430.3 ± 0.350.1 ± 0.530.5 ± 0.630.9 ± 0.610.1 ± 0.42
Enjoyment of life0.8 ± 0.460.6 ± 0.410.4 ± 0.340.2 ± 0.691.1 ± 0.710.8 ± 0.52
Pain Interference Scale0.8 ± 0.340.4 ± 0.300.7 ± 0.420.3 ± 0.560.9 ± 0.480.4 ± 0.36
Statistical analysis
  • Phase 2 (Palbociclib + Letrozole) vs Phase 2 (Letrozole) · t-test, 2 sided · p = 0.3346 (P-values are based on 2-sample t-test.) · Mean difference (final values): 0.4 · 95% CI -0.5 to 1.3
  • Ph2P1 (Palbociclib + Letrozole) vs Ph2P1 (Letrozole) · t-test, 2 sided · p = 0.5630 (P-values are based on 2-sample t-test.) · Mean difference (final values): 0.4 · 95% CI -1.0 to 1.9
  • Ph2P2 (Palbociclib + Letrozole) vs Ph2P2 (Letrozole) · t-test, 2 sided · p = 0.4427 (P-values are based on 2-sample t-test.) · Mean difference (final values): 0.5 · 95% CI -0.7 to 1.6
SecondaryPresence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1

Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples.

Time frame:
Screening visit (≤ 28 Days prior to dosing)
Reported as:
Number · Participants
Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1
ParticipantsPh2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
CCND1>=1.512 ± 0.669 ± 0.5839 ± 0.5144 ± 0.37
p16/INK4A<0.80 ± 0.722 ± 0.6219 ± 0.6912 ± 0.44
CCND1>=1.5 and p16/INK4A<0.80 ± 0.552 ± 0.638 ± 0.678 ± 0.43
SecondaryPresence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67

Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups.

Time frame:
Screening visit (≤ 28 Days prior to dosing)
Reported as:
Number · Participants
Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67
ParticipantsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
<=20%26 ± 0.4031 ± 0.317 ± 0.6616 ± 0.5819 ± 0.5115 ± 0.37
>20%48 ± 0.5040 ± 0.3617 ± 0.7210 ± 0.6231 ± 0.6930 ± 0.44
SecondaryPresence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1

Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression \>0 and Negative: any expression=0.

Time frame:
Screening visit (≤ 28 Days prior to dosing)
Reported as:
Number · Participants
Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1
ParticipantsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
CyclinD1 - Positive41 ± 0.4032 ± 0.3110 ± 0.6616 ± 0.5831 ± 0.5116 ± 0.37
CyclinD1 - Negative3 ± 0.503 ± 0.362 ± 0.720 ± 0.621 ± 0.693 ± 0.44
RB - Positive413210163116
RB - Negative222002
SecondarySummary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2

Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group.

Time frame:
Screening visit (≤ 28 Days prior to dosing)
Reported as:
Mean · Copy number
Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2
Copy numberPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)
CCND12.76 ± 1.8752.73 ± 1.559
p16/INK4A0.83 ± 0.2240.87 ± 0.173
SecondaryPercentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2

One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed.

Time frame:
Screening visit (≤ 28 Days prior to dosing)
Reported as:
Number · Percentage of participants
Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2
Percentage of participantsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
CYP19A1 - A/A Genotype7.9 ± 0.425.4 ± 0.4210.0 ± 0.6010.7 ± 0.896.5 ± 0.552.2 ± 0.43
CYP19A1 - C/A Genotype34.2 ± 0.2736.5 ± 0.2733.3 ± 0.3142.9 ± 0.5034.8 ± 0.4032.6 ± 0.31
CYP19A1 - C/C Genotype57.9 ± 0.3358.1 ± 0.3456.7 ± 0.4846.4 ± 0.6458.7 ± 0.4565.2 ± 0.40
CCND1 - A/A Genotype26.3 ± 0.3528.4 ± 0.3633.3 ± 0.3139.3 ± 0.6621.7 ± 0.5521.7 ± 0.43
CCND1 - G/A Genotype47.4 ± 0.2947.3 ± 0.3243.3 ± 0.3642.9 ± 0.6250.0 ± 0.4150.0 ± 0.36
CCND1 - G/G Genotype26.324.323.317.928.328.3
SecondaryNumber of Participants With TEAEs (All Causalities) at Phase 2

AE:any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non-serious AEs.SAE:AE resulting in any of following outcomes/deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason:death;initial or prolonged inpatient hospitalization;life-threatening experience (immediate risk of dying);persistent or significant disability/incapacity;congenital anomaly.Treatment emergent AEs:events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or worsened relative to pre-treatment state.AEs were graded as per the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and coded using Medical Dictionary for Regulatory Activities (MedDRA). Participants with AE of grade 3 or 4 and grade 5 were reported as Grade 3:Severe, Grade 4:Life threatening, Grade 5:Death related to AE.

Time frame:
Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs (All Causalities) at Phase 2
ParticipantsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Participants with AEs836633255041
Participants with SAEs226102124
Participants with Grade 3 or 4 AEs70192954114
Participants with Grade 5 AEs100010
SecondaryNumber of Participants With Treatment-Related Adverse Events at Phase 2

AE: any untoward medical occurrence in a participant who received study drug. AEs included both serious and non-serious adverse events. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs: events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Treatment related AEs: all AEs with causality related to treatment. Relatedness to drug was assessed by the investigator. AEs were graded according to the CTCAE version 3.0 and coded using the MedDRA. Number of participants with AE of grade 3 or 4 and with AE of grade 5 were reported as Grade 3: Severe, Grade 4: Life threatening, Grade 5: Death related to AE.

Time frame:
Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Adverse Events at Phase 2
ParticipantsPhase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Participants with AEs783332134620
Participants with SAEs100010
Participants with Grade 3 or 4 AEs572250322
Participants with Grade 5 AEs000000

Adverse events

Collected over Baseline up to 28 days after last dose of study drug (for a maximum of 86 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 (Palbociclib + Letrozole)0/12 (0%)2/12 (16.7%)12/12 (100%)
Phase 2 (Palbociclib + Letrozole)3/83 (3.6%)22/83 (26.5%)83/83 (100%)
Phase 2 (Letrozole)1/77 (1.3%)6/77 (7.8%)57/77 (74%)
Ph2P1 (Palbociclib + Letrozole)1/33 (3%)10/33 (30.3%)33/33 (100%)
Ph2P1 (Letrozole)0/29 (0%)2/29 (6.9%)22/29 (75.9%)
Ph2P2 (Palbociclib + Letrozole)2/50 (4%)12/50 (24%)50/50 (100%)
Ph2P2 (Letrozole)1/48 (2.1%)4/48 (8.3%)35/48 (72.9%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventPhase 1 (Palbociclib + Letrozole)Phase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/124/830/774/330/290/500/48
PainGeneral disorders1/121/830/771/330/290/500/48
NauseaGastrointestinal disorders1/120/830/770/330/290/500/48
VomitingGastrointestinal disorders1/120/830/770/330/290/500/48
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/122/830/770/330/292/500/48
IleusGastrointestinal disorders0/120/831/770/331/290/500/48
Subcutaneous emphysemaSkin and subcutaneous tissue disorders0/120/831/770/331/290/500/48
Gastrointestinal disorderGastrointestinal disorders0/121/830/771/330/290/500/48
AstheniaGeneral disorders0/121/830/771/330/290/500/48
Chest painGeneral disorders0/121/830/771/330/290/500/48
Most frequent other events
Showing 10 of 166
Most frequent other events
EventPhase 1 (Palbociclib + Letrozole)Phase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Ph2P1 (Palbociclib + Letrozole)Ph2P1 (Letrozole)Ph2P2 (Palbociclib + Letrozole)Ph2P2 (Letrozole)
NeutropeniaBlood and lymphatic system disorders11/1262/834/7726/331/2936/503/48
FatigueGeneral disorders10/1234/8318/7714/337/2920/5011/48
LeukopeniaBlood and lymphatic system disorders8/1236/833/7716/331/2920/502/48
DiarrhoeaGastrointestinal disorders6/1218/839/779/332/299/507/48
NauseaGastrointestinal disorders6/1225/8311/7712/337/2913/504/48
ArthralgiaMusculoskeletal and connective tissue disorders5/1222/8314/779/335/2913/509/48
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1214/837/774/333/2910/504/48
AnaemiaBlood and lymphatic system disorders4/1229/833/7713/330/2916/503/48
HeadacheNervous system disorders4/1212/838/776/333/296/505/48
VomitingGastrointestinal disorders3/1215/833/779/332/296/501/48

Baseline characteristics

Analysis was done on participants who received at least one dose of study drug.

Age, Customized
Age, Customized(Participants)Phase 1 (Palbociclib + Letrozole)Phase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Total
<18 Years0000
18-44 Years1247
45-64 Years6453889
>= 65 Years5373981
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 (Palbociclib + Letrozole)Phase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Total
Female128481177
Male0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1 (Palbociclib + Letrozole)Phase 2 (Palbociclib + Letrozole)Phase 2 (Letrozole)Total
American Indian or Alaska Native0000
Asian06410
Native Hawaiian or Other Pacific Islander0000
Black or African American0112
White117672159
More than one race0000
Unknown or Not Reported1146
08

Study locations

104 sites
  • Central Hematology Oncology Medical group Inc.
    Alhambra, California 91801, United States
  • UCLA Hematology/Oncology - Alhambra
    Alhambra, California 91801, United States
  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • St. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • UCLA West Medical Pharmacy (Drug Management Only)
    Los Angeles, California 90095-1772, United States
  • UCLA West Medical Pharmacy
    Los Angeles, California 90095-1772, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095-6984, United States
  • UCLA West Medical Pharmacy
    Los Angeles, California 90095-7349, United States
  • Drug Management Only: UCLA West Medical Pharmacy
    Los Angeles, California 90095, United States
  • Drug Management Only
    Los Angeles, California 90095, United States
  • Regulatory Managment
    Los Angeles, California 90095, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • TORI -US Central Administration (Regulatory Management)
    Los Angeles, California 90095, United States
  • TORI -US Central Administration
    Los Angeles, California 90095, United States
  • TORI Central Administration (Regulatory Management)
    Los Angeles, California 90095, United States
  • TORI Central Administration (Regulatory Managment Only)
    Los Angeles, California 90095, United States
  • TRIO-US Central Administration
    Los Angeles, California 90095, United States
  • UCLA Hematology/Oncology
    Los Angeles, California 90095, United States
  • UCLA, Hematology/Oncology
    Los Angeles, California 90095, United States
  • Westwood Bowyer Clinic, Peter Morton Medical Building
    Los Angeles, California 90095, United States
  • Central Hematology Oncology Medical Group, Inc
    Pasadena, California 91107, United States
  • Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates
    Redondo Beach, California 90277, United States
  • Sansum Santa Barbara Medical Foundation Clinic
    Santa Barbara, California 93105, United States
  • Central Coast Medical Oncology Corporation
    Santa Maria, California 93454, United States
  • Santa Monica-UCLA Medical Center and Orthopaedic Hospital
    Santa Monica, California 90404, United States
  • UCLA Hematology Oncology-Santa Monica
    Santa Monica, California 90404, United States
  • UCLA Hematology/Oncology - Santa Clarita
    Valencia, California 91355, United States
  • Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care
    Duluth, Georgia 30096, United States
  • Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care
    Lawrenceville, Georgia 30046, United States
  • Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care
    Snellville, Georgia 30078, United States
  • Illinois Cancer Specialists
    Chicago, Illinois 60611, United States
  • Resurrection Medical Group
    Chicago, Illinois 60657, United States
  • North Shore Oncology-Hematology Associates
    Crystal Lake, Illinois 60014, United States
  • North Shore Hematology Oncology
    Highland Park, Illinois 60035, United States
  • North Shore Oncology-Hematology Associates
    Libertyville, Illinois 60048, United States
  • North Shore Hematology Oncology
    Skokie, Illinois 60077, United States
  • Regulatory Office: Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89014, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89052, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89074, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89128, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89148, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Texas Oncology-Dallas Presbyterian Hospital
    Dallas, Texas 75231, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Investigational Products Center (IPC)
    Fort Worth, Texas 76177, United States
  • US Oncology Research and Clinical Pharmacy
    Fort Worth, Texas 76177, United States
  • Virginia Cancer Specialists, PC
    Arlington, Virginia 22205, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Virginia Cancer Specialists, PC
    Gainesville, Virginia 20155, United States
  • Virginia Cancer Specialists, PC
    Leesburg, Virginia 20176, United States
  • Virginia Cancer Specialists, PC
    Woodbridge, Virginia 22191, United States
  • BC Cancer Agency - Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • CSSS Champlain-Charles-Le Moyne Local HS-0054
    Greenfield Park, Quebec J4V 2H1, Canada
  • Centre Paul Papin, CRLCC
    ANGERS Cedex 9, 49933, France
  • CHD Vendee
    La Roche Sur Yon, 85925, France
  • Gemeinschaftspraxis, Onkologischer Schwerpunkt am Oskar-Helene-Heim
    Berlin, 14195, Germany
  • Gemeinschaftspraxis Haematologie-Onkologie
    Dresden, 01307, Germany
  • Martin-Luther-Universitaet Halle-Wittenberg
    Halle/Saale, 06097, Germany
  • Universitaetsklinik und Poliklinik fuer Gynaekologie, Martin-Luther-Universitaet Halle-Wittenberg
    Halle/Saale, 06120, Germany
  • Nationales Centrum fuer Tumorerkrankungen
    Heidelberg, 69120, Germany
  • Frauenaerzte Pruener Gang Abts & Partner
    Kiel, 24103, Germany
  • Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Universitaetsklinik Mainz
    Mainz, 55101, Germany
  • Onkolog. Gemeinschaftspraxis
    Muenchen, 80335, Germany
  • Frauenklinik vom Roten Kreuz
    Muenchen, 80637, Germany
  • Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universitaet Muenchen
    Muenchen, 81675, Germany
  • Mutterhaus der Borromaeerinnen, Innere Medizin I
    Trier, 54290, Germany
  • Szent Margit Korhaz, Onkologia
    Budapest, 1032, Hungary
  • Orszagos Onkologiai Intezet, Kemoterapia B
    Budapest, 1122, Hungary
  • Fovarosi Onkormanyzat Uzsoki Utcai Korhaz
    Budapest, 1145, Hungary
  • Petz Aladar Megyei Oktato Korhaz, Onkoradiologia
    Gyor, 9023, Hungary
  • Borsod-Abauj-Zemplen Megyei Korhaz és Egyetemi Oktato Korhaz, Onkologia
    Miskolc, 3526, Hungary
  • Szabolcs-Szatmar-Bereg Megyei Korhazak es
    Nyiregyhaza, 4400, Hungary
  • Markusovszky Egyetemi Oktatokorhaz, Onkoradiologiai Osztaly
    Szombathely, 9700, Hungary
  • Bon Secours Hospital
    Cork, Ireland
  • St. James's Hospital
    Dublin 8, Ireland
  • St. Vincent's University Hospital
    Dublin, 4, Ireland
  • Mater Misericordiae University Hospital
    Dublin, 7, Ireland
  • Mater Private Hospital
    Dublin, 7, Ireland
  • Divisione Oncologia Medica Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST
    Meldola, FC 47014, Italy
  • M.O. di Oncologia - Azienda USL di Rimini - Ospedale "Cervesi"
    Cattolica, 47841, Italy
  • Ospedale Civile di Faenza Centro Oncologico
    Faenza, RA, 48018, Italy
  • Unita' Operativa di Oncologia, Ospedale Civile di Lugo
    Lugo, RA, 48022, Italy
  • Ospedale Civile di Ravenna
    Ravenna, 48100, Italy
  • Azienda Unita Sanitaria Locale di Rimini, U.O. di Oncologia ed Oncoematologia Ospedale degli Infermi
    Rimini, 47900, Italy
  • Ospedale Villa San Pietro
    Roma, 00189, Italy
  • National Cancer Center, Center for Breast Cancer
    Goyang-si, Gyeonggi-do 10408, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Federal State Budgetary Scientific Institution
    Moscow, 115478, Russian Federation
  • Pyatigorsk Oncology Center
    Pyatigorsk, 357502, Russian Federation
  • State Budgetary Healthcare Institution "Samara Regional Clinical Oncology Dispensary"
    Samara, 443031, Russian Federation
  • Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic
    Ufa, 450054, Russian Federation
  • Department of Oncotherapy, National Hospital
    Bloemfontein, 9301, South Africa
  • Eastleigh Breast Care Centre
    Pretoria, 0041, South Africa
  • Ico-Hospitalet
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital General Universitario Vall D'Hebron
    Barcelona, 08035, Spain
  • Centro Oncologico de Galicia
    La Coruña, 15009, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, 41013, Spain
  • Department of Oncology and Medical Radiology, SI "DMA of MOH, Ukraine, "MI "Dnipropetrovsk City
    Dnipropetrovsk, 49102, Ukraine

Showing the first 100 of 104 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, Schnell P, Lu DR, Theall KP, Mori A, Gauthier E, Bananis E, Turner NC, Dieras V. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. Oncologist. 2021 May;26(5):e749-e755. doi: 10.1002/onco.13684. Epub 2021 Mar 10. PubMed 33486783 ↗
  • Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, Shparyk YV, Thummala A, Voitko N, Bananis E, McRoy L, Wilner K, Huang X, Kim S, Slamon DJ, Ettl J. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020 Sep;183(2):419-428. doi: 10.1007/s10549-020-05755-7. Epub 2020 Jul 18. PubMed 32683565 ↗
  • Ettl J, Im SA, Ro J, Masuda N, Colleoni M, Schnell P, Bananis E, Lu DR, Cristofanilli M, Rugo HS, Finn RS. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Res. 2020 Mar 12;22(1):27. doi: 10.1186/s13058-020-01263-0. PubMed 32164785 ↗
  • Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018 Sep;101:123-133. doi: 10.1016/j.ejca.2018.05.017. Epub 2018 Jul 25. PubMed 30053671 ↗
  • Dieras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. J Natl Cancer Inst. 2019 Apr 1;111(4):419-430. doi: 10.1093/jnci/djy109. PubMed 30032196 ↗
  • Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9. PubMed 29522361 ↗
  • Bell T, Crown JP, Lang I, Bhattacharyya H, Zanotti G, Randolph S, Kim S, Huang X, Huang Bartlett C, Finn RS, Slamon D. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment. Curr Med Res Opin. 2016 May;32(5):959-65. doi: 10.1185/03007995.2016.1157060. Epub 2016 Mar 2. PubMed 26894413 ↗
  • Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. PubMed 25524798 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Nov 2013, 62 months.

Results were first posted in Mar 2015, 1 year 3 months after primary completion. A results delay was requested in Dec 2014.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 62 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2008
First posted
Jul 24, 2008
StartActual
Sep 15, 2008
Primary completionActual
Nov 29, 2013
CompletionActual
Dec 20, 2017
Results delay requested
Dec 5, 2014
Results first posted
Mar 19, 2015
Last update
Nov 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00721409
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 24, 2008
Start date
Sep 15, 2008
Primary completion
Nov 29, 2013
Completion
Dec 20, 2017
Results posted
Mar 19, 2015
Last update
Nov 4, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion